Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an <i>LDL Receptor</i> Mutation and a <i>PCSK9</i> V4I Mutation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation

Published:2018-12-15 Issue:24 Volume:57 Page:3551-3557
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Shirahama Ryo¹,Ono Takamichi¹,Nagamatsu Suguru²,Sueta Daisuke²,Takashio Seiji²,Chitose Tadasuke¹,Fujisue Koichiro²,Sakamoto Kenji²,Yamamoto Eiichiro²,Izumiya Yasuhiro²,Kaikita Koichi²,Hokimoto Seiji²,Hori Mika³,Harada-Shiba Mariko³,Kajiwara Ichiro¹,Ogawa Hisao⁴,Tsujita Kenichi²

Affiliation:

1. Department of Cardiovascular Medicine, Arao City Hospital, Japan

2. Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan

3. Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan

4. National Cerebral and Cardiovascular Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/24/57_1060-18/_pdf

Reference33 articles.

1. 1. Bujo H, Takahashi K, Saito Y, et al. Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the Research Committee of the Ministry of Health, Labour and Welfare of Japan. J Atheroscler Thromb 11: 146-151, 2004.

2. 2. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126: 2408-2417, 2012.

3. 3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376: 1713-1722, 2017.

4. 4. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316: 2373-2384, 2016.

5. 5. Ohta N, Hori M, Takahashi A, et al. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. J Clin Lipidol 10: 547-555.e55, 2016.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low-density lipoprotein cholesterol reduction is associated with computed tomography angiography signs of regression and stabilization of coronary plaque: from the TARGET trial;Cardiology Plus;2023-10

2. LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy;Journal of Clinical Laboratory Analysis;2021-10-15

3. The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype–Phenotype Correlations of the Disease;Frontiers in Genetics;2021-01-15

4. Biomarkers;Principles of Translational Science in Medicine;2021

5. Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature;Journal of Clinical Lipidology;2020-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3